XML 21 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 2 - Fair Value Measurement
3 Months Ended
Mar. 31, 2015
Notes to Financial Statements  
Fair Value Disclosures [Text Block]
2
.
Fair value measurement
 
As a basis for determining the fair value of certain of the Company’s financial instruments, the Company utilizes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
 
Level I—Observable inputs such as quoted prices in active markets for identical assets or liabilities.
 
Level II—Observable inputs, other than Level I prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
 
Level III—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
 
This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The carrying amount of certain of the Company’s financial instruments, including cash, accounts receivable, prepaid expenses and other assets, accounts payable, and accrued liabilities approximate fair value due to their short maturities.
 
Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability.
 
The following tables present information about the balances of liabilities measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques it utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates, and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. The Company did not have any financial assets measured at fair value on a recurring basis.
 
 
 
 
 
 
 
Fair
v
alue
m
easurements
at
March 31, 2015 us
ing
 
(in thousands)
 
March 31, 2015
 
 
Quoted
p
rices
in
a
ctive
m
arkets
f
or
i
dentical
a
ssets
(Level
1)
 
 
Significant
o
ther
o
bservable
i
nputs
(Level 2)
 
 
Significant
u
nobservable
i
nputs
(Level 3)
 
Liabilities:
                               
Contingent purchase price consideration
  $ 1,126     $     $     $ 1,126  
Total
  $ 1,126     $     $     $ 1,126  
 
 
 
 
 
 
 
Fair
v
alue
m
easurements
at
December 31, 2014 us
ing
 
(in thousands)
 
December 31, 2014
 
 
Quoted
p
rices
in
a
ctive
m
arkets
f
or
i
dentical
a
ssets
(Level
1)
 
 
Significant
o
ther
o
bservable
i
nputs
(Level 2)
 
 
Significant
u
nobservable
i
nputs
(Level 3)
 
Liabilities:
                               
Contingent purchase price consideration
  $ 1,218     $     $     $ 1,218  
Total
  $ 1,218     $     $     $ 1,218  
 
On July 31, 2014, the Company acquired substantially all of the assets of Boulder Diagnostics, Inc., or Boulder, a privately owned company developing immunology-based assays for autoimmune and inflammatory conditions/diseases. The terms of the purchase agreement included contingent purchase price consideration consisting of future potential milestone payments totaling up to $6.1 million at any time on or prior to July 31, 2024. The milestone payments consist of completion of studies related to acquired technologies, development of diagnostic test kits, patient enrollment in an Institutional Review Board approved study, issuance of patents, and approvals or clearances by the U.S. Food and Drug Administration, or FDA. The fair value of future potential milestone payments was determined based upon a probability weighted analysis of expected future milestone payments to be made to the seller, which are considered as Level 3 inputs.
 
The following table provides a summary of changes in the fair value of the Company's Level 3 financial liabilities for the three-month period ended March 31, 2015 (in thousands):
 
Balance – beginning
  $ 1,218  
Change in fair value of contingent purchase price consideration
    47  
Foreign currency adjustment
    (139 )
Balance – ending
  $ 1,126